Krystal Biotech Q1 Earnings Call Highlights

Key Points

• Krystal reported Q1 net revenue of $116.4 million from VYJUVEK with a 95% gross margin, net income of $55.9 million, and ended the quarter with more than $1 billion in cash and investments while maintaining full‑year non‑GAAP op‑expense guidance of $175–195 million.
• U.S. net sales were $87.5 million but showed quarter-to-quarter variability due to insurance switchovers and patient “start‑stop” maintenance dosing, while international markets (Europe + Japan) contributed $28.9 million as launches expand and Italy and Spain are targeted for potential H2 2026 rollouts.
• Krystal expects two registrational readouts later this year—including KB801 (neurotrophic keratitis) and KB803 (DEB corneal abrasions, supporting a Q4 2026 readout)—with additional trials (KB407, KB111) advancing and further data updates, including a KB707 update at ASCO, slated into 2027.

Krystal Biotech NASDAQ: KRYS reported first-quarter 2026 net revenue of $116.4 million from global sales of VYJUVEK, supported by continued demand in the U.S. and early traction in Europe and Japan. Management highlighted positive operating leverage, a 95% gross margin, and an expanding clinical pipeline with multiple data readouts expected later this year.

VYJUVEK revenue growth continues as international contribution expands

Chairman and CEO Krish Krishnan said the company delivered “another quarter of global revenue growth,” with Q1 net VYJUVEK revenue of $116.4 million and cumulative net revenue since launch exceeding $846 million. Krishnan noted the quarter represented 9% sequential growth versus the fourth quarter of 2025 despite “a higher than usual level of insurance changes” typical of first quarters for commercial-stage biotech companies.

Chief Accounting Officer Kathryn Romano said Q1 net revenue increased 32% compared to the first quarter of 2025. Cost of goods sold was $6.3 million, and gross margin was 95%, slightly up from 94% a year earlier. Romano attributed the margin performance to manufacturing process improvements for the U.S.-approved product and said the company is working to achieve similar efficiencies for other markets.

International markets accounted for a meaningful portion of the quarter. Laurent Goux, EVP and general manager for Europe, said Europe plus Japan contributed $28.9 million in net revenue. He estimated that more than 140 dystrophic epidermolysis bullosa (DEB) patients have been prescribed VYJUVEK across Germany, Japan, and France, citing expanding physician engagement and a broadening prescriber base.

U.S. dynamics shaped by insurance switchovers and “start-stop” maintenance patterns

Senior Vice President and head of U.S. commercial Christine Wilson reported U.S. net VYJUVEK revenue of $87.5 million for the quarter. Wilson said results were impacted by insurance switchovers and by the “start-stop treatment cadence” as the treated population increasingly shifts toward maintenance regimens. She said the company has secured more than 695 reimbursement approvals for DEB patients nationwide and added over 60 new prescribers during the first quarter, bringing the total to more than 570 unique prescribers since launch.

Krishnan told analysts that underlying demand continues to grow, but quarterly revenue can be difficult to predict due to patients pausing and restarting treatment as wounds heal and later recur. “On a Q-by-Q basis, it’s fairly tough to predict the ups and downs,” he said, adding that the company expects the overall trend to be positive.

When asked about insurer friction around treatment “drug holidays” and restarts, Krishnan said the company has had “no issues with access to date,” including reimbursement and reauthorization, and said restarts have been “really smooth.”

Wilson also pointed to the impact of label updates that increased administration flexibility. She said the updates have been well received by patients and physicians and have helped some patients initiate therapy who previously were uncomfortable with home nursing, while others have transitioned from nurse support to self-administration.

Europe and Japan launch progresses; additional markets targeted for 2026

Goux emphasized that the ex-U.S. rollout is progressing “market by market, physician by physician, and patient by patient,” with word-of-mouth from key centers supporting awareness and demand. He said pricing negotiations are ongoing in Germany and France, with the company expecting a decision in Germany in the second half of 2026 and a decision in France in 2027.

Goux said the company is advancing discussions in Italy and preparing for a potential launch in the second half of 2026, pending negotiations. He added that discussions in Spain have accelerated, creating a potential opportunity to launch there in the second half of the year, also pending negotiations. In response to an analyst question, Goux said the company expects definitive reimbursement in Italy and Spain rather than the type of advanced access models currently used in Germany and France.

Krishnan said European and Japanese physicians have been easier to bring up to speed than in the U.S. because the region launched later and clinicians are already aware of the benefits seen in U.S. patients. He added that negotiations can be influenced by political and macroeconomic factors, including rare disease budgets, but said the company feels it can make a compelling value proposition based on clinical benefit.

Pipeline: two registrational readouts expected later this year, with more in 2027

President of R&D Suma Krishnan said Krystal expects two registrational study readouts later this year and two more in 2027, alongside additional clinical updates across the pipeline.

• KB803 (ophthalmology, DEB corneal abrasions): Suma Krishnan said enrollment is complete in IOLITE, a registrational study evaluating KB803 for treatment and prevention of corneal abrasions in DEB patients. Sixteen patients were enrolled in the randomized, intra-patient, double-blind, decentralized, placebo-controlled crossover study. The primary endpoint is change from baseline in average number of days per month with symptoms, assessed at 24 weeks, supporting a fourth-quarter 2026 readout.
• KB801 (neurotrophic keratitis): She said the registrational study is progressing, targets enrollment of 60 patients, is an eight-week study, and remains on track for a data readout later this year.
• KB407 (cystic fibrosis): Suma Krishnan said the company is initiating an open-label, single-arm repeat-dose safety study over 24 weeks in five CF patients ineligible for, intolerant of, or not benefiting from modulator therapy, with dosing expected to start later in the month and enrollment expected to complete later in the quarter. The primary endpoint is safety, with exploratory assessments including FEV1 and patient-reported outcomes. She said the FDA’s feedback centered on the need to establish repeat-dose safety, and that the company is working with the Cystic Fibrosis Foundation and the FDA on a registrational trial design and statistical analysis plan, with alignment expected in the second half of 2026 and a registrational study start in the first half of 2027.
• KB111 (Hailey-Hailey disease): She said the company is developing and validating an HHD severity scale and expects to complete both in the first half of the year. Krystal plans to initiate an open-label safety study (HALITE-1) in seven patients for 12 weeks, dose the first patient later this month, and submit a registrational study design to the FDA in the second half of 2026. She said the registrational study is expected to start in 2027, citing the need to validate the patient-reported outcome scale and better characterize the disease in an initial small study before moving into registration.

Suma Krishnan also said the KB408 program for AATD lung disease and KB707 for non-small cell lung cancer are advancing in the clinic, with data updates expected later this year, including a KB707 update at ASCO next month.

Profitability, expense trends, and cash position

Romano reported net income of $55.9 million for the quarter, or $1.91 per basic share and $1.83 per diluted share, compared to net income of $35.7 million a year earlier. She said R&D expense was $15.3 million versus $14.3 million in the prior-year quarter, driven mainly by payroll, materials, and support costs for production runs across multiple candidates. G&A expense was $41.0 million versus $32.6 million, primarily due to increased headcount and compensation, as well as higher legal consulting and global launch support costs for VYJUVEK.

Romano said the company’s previously issued guidance on non-GAAP operating expenses remains unchanged, with expected full-year 2026 non-GAAP R&D and SG&A expenses of approximately $175 million to $195 million. She also said Krystal ended the quarter with more than $1 billion in combined cash and investments.

On capital allocation, Krishnan said the company remains in “growth mode” across commercialization and the pipeline and is not planning on licensing or acquisitions. He said the company would consider broader capital allocation decisions once it has greater visibility into the future of the pipeline and potential launches of additional products.

About Krystal Biotech NASDAQ: KRYS

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.